| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.061 | 0.2 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.072 | 0.2 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | AZD0530 | FIMM | pan-cancer | AAC | -0.2 | 0.2 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |